Recurrent Herpes Simplex Labialis
Conditions
Brief summary
Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
Detailed description
This is a randomized, double-blind, two arm, parallel-group, vehicle-controlled, multi-center study of NB-001. The study is designed to demonstrate the safety and efficacy of NB-001 in subjects with RHL. Approximately 850 subjects who meet all eligibility criteria will be randomized in the study. Subjects will begin treatment as soon as they experience the onset of cold sore symptoms. Treatment will be applied 5 times daily, approximately 3-4 hours apart while awake. Treatment will continue until the investigator assesses the primary lesion complex as healed or a maximum of 4 days. Clinic visits will occur on a daily basis until the investigator determines that the primary lesion complex has healed or a maximum of 15 clinic visits. At daily clinic visits, the investigator will make efficacy assessments of the primary lesion complex; safety and tolerability assessments of NB-001 following topical administration will also be assessed daily. Subjects will make daily assessments of therapy. At the End of Study, the investigator will make a global assessment of therapy. The subject will make global assessments of therapy and social impact.
Interventions
DRUGVehicle versus NB-001
Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
Sponsors
NanoBio Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* A Healthy man or woman 18 years of age or older. Women who are pregnant, lactating or may become pregnant may (at the investigator's discretion) be included in the study. * Have recurrent herpes labialis as defined by a history of three (3) or more cold sore recurrences on the lips and/or skin surrounding the lips in the previous 12 months; * Have the majority of their cold sore recurrences proceeded by a well defined history of prodromal symptoms.
Exclusion criteria
* Subjects with severe chronic illness * Received (within the last 6 months) or receiving chemotherapy; * Significant skin disease on the face * Previously received herpes vaccine; * Active alcohol or drug abuse; * Prior randomization into any NanoBio study; * Known allergies to topical creams, ointments or other topical medications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time of Healing of the primary lesion complex | Days | Time to healing of the primary lesion complex (in days or fraction thereof) as assessed by the investigator. Time to healing is the time from application of the first dose to investigator assessed healing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects in whom the primary lesion complex does not progress beyond the Papule/Edema Stage. | First Post-Treatment Visit | Proportion of subjects in whom the primary lesion complex does not progress beyond the Papule/Edema Stage. This analysis will be performed in the cohort of subjects whose primary lesion complex is assessed as being in the Prodrome (pain, burning, tingling, itching, redness, swelling, or a tight sensation of the lip), Erythema/Macule, Papule/Edema, or Aborted Stage by the investigator at the first post-treatment visit. |
Countries
United States
Outcome results
None listed